
## **Ulrike Schmidt**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8267691/publications.pdf Version: 2024-02-01



HIDIKE SCHMIDT

#	Article	IF	CITATIONS
1	Digital psychological first aid for Ukraine. Lancet Psychiatry,the, 2022, 9, e33.	3.7	9
2	Molecular and neurocircuitry mechanisms of social avoidance. Cellular and Molecular Life Sciences, 2021, 78, 1163-1189.	2.4	21
3	Robustly High Hippocampal BDNF levels under Acute Stress in Mice Lacking the Full-length p75 Neurotrophin Receptor. Pharmacopsychiatry, 2021, 54, 205-213.	1.7	5
4	Stress-primed secretory autophagy promotes extracellular BDNF maturation by enhancing MMP9 secretion. Nature Communications, 2021, 12, 4643.	5.8	50
5	Oxytocin receptor is a potential biomarker of the hyporesponsive HPA axis subtype of PTSD and might be modulated by HPA axis reactivity traits in humans and mice. Psychoneuroendocrinology, 2021, 129, 105242.	1.3	7
6	MMP9 mRNA is a potential diagnostic and treatment monitoring marker for PTSD: Evidence from mice and humans. European Neuropsychopharmacology, 2021, 51, 20-32.	0.3	6
7	Analysis of the cerebellar molecular stress response led to first evidence of a role for FKBP51 in brain FKBP52 expression in mice and humans. Neurobiology of Stress, 2021, 15, 100401.	1.9	6
8	Novel treatment targets for COVID-19: Contribution from molecular psychiatry. World Journal of Biological Psychiatry, 2020, 21, 572-575.	1.3	1
9	Posttraumatic growth during cognitive behavioural therapy for posttraumatic stress disorder: Relationship to symptom change and introduction of significant other assessment. Stress and Health, 2019, 35, 617-625.	1.4	3
10	The Dissociative Subtype of PTSD Interview (DSP-I): Development and Psychometric Properties. Journal of Trauma and Dissociation, 2019, 20, 564-581.	1.0	17
11	The Hypothalamic-Pituitary-Adrenal Axis in Depression: Molecular Regulation, Pathophysiological Role, and Translational Implications. , 2019, , 89-96.		10
12	PTSD psychotherapy improves blood pressure but leaves HPA axis feedback sensitivity stable and unaffected: First evidence from a pre-post treatment study. Psychoneuroendocrinology, 2019, 100, 254-263.	1.3	16
13	Polymorphism in Tmem132d regulates expression and anxiety-related behavior through binding of RNA polymerase II complex. Translational Psychiatry, 2018, 8, 1.	2.4	263
14	Integrating NIMH Research Domain Criteria (RDoC) into PTSD Research. Current Topics in Behavioral Neurosciences, 2017, 38, 69-91.	0.8	28
15	New insights into the intracellular distribution pattern of cationic amphiphilic drugs. Scientific Reports, 2017, 7, 44277.	1.6	21
16	Azidobupramine, an Antidepressant-Derived Bifunctional Neurotransmitter Transporter Ligand Allowing Covalent Labeling and Attachment of Fluorophores. PLoS ONE, 2016, 11, e0148608.	1.1	5
17	Posttraumatic Growth in Populations with Posttraumatic Stress Disorder—A Systematic Review on Growthâ€Related Psychological Constructs and Biological Variables. Clinical Psychology and Psychotherapy, 2016, 23, 469-486.	1.4	84
18	The brain as immunoprecipitator of serum autoantibodies against Nâ€Methylâ€Dâ€aspartate receptor subunit NR1. Annals of Neurology, 2016, 79, 144-151.	2.8	75

**ULRIKE SCHMIDT** 

19       A plea for symptom-based research in psychiatry. HAfgre Utbildning. 2015, 6, 27660.       1.4       20         20       Intransally Applied Neuropertide S Shifts a High-Axiety Decrephysiological Endophenotype in the Ventral Hippocampus towards a "Normal" Axiety One. PLoS ONE, 2015, 10, e0120272.       1.1       20         21       Searching for non-genetic molecular and imaging PTSD field and resilience markers: Systematic review of Interacture and degin of the German Armel Forces PTSD biomather study. Psychoneuroendocrinology, 2015, 51, 1244-458.       1.3       29         22       Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD       1.3       74         23       mRNAs and other non-coding RNAs in postraumatic stress deorder: A systematic review of clinical and animal studies. Journal of Psychiatric Research, 2015, 55, 102-115.       1.5       28         24       Improvement of nonsuledal self-lighty following treatment with antipsychotics possessing strong D1 and animal studies. Psychoneuroendocrinology, 2015, 51, 244-58.       1.3       26         24       Improvement of nonsuledal self-lighty following treatment with antipsychotics possessing strong D1 and animal studies. Psychoneuroendocrinology, 2015, 51, 244-58.       1.3       26         24       Improvement of nonsuledal self-light following treatment with antipsychotics possessing strong D1 and animal studies. Psychoneuroendocrinology, 2015, 51, 244-58.       1.3       26         25       Arole for synapsin In FRDF51 modulation of str	#	Article	IF	CITATIONS
20       Ventral Hippocampus towards a "Normal" Anxiety One. PLoS ONE, 2015, 10, e0120272.       11       20         21       Searching for non-genetic molecular and imaging PTSD rick and resilience markers: Systematic review of literature and design of the German Annuel Forces PTSD biomarker study. Psychoneuroendocrinology, 2015, 51, 4444-98.       1.3       29         22       Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients. Psychoneuroendocrinology, 2015, 55, 102-115.       1.3       74         29       miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical and animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       1.5       28         24       Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Therapeutic Advances in Psychopharmacology, 2015, 9, 208-213.       20         25       Arole for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.       1.3       26         26       The FKBP51-Clucocorticoid Receptor Balance in Stress-Related Mental Disorders. Current Molecular Pharmacology, 2015, 9, 126-140.       0.7       33         27       Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease Markers, 2013, 35, 43-54.       1.3       47         28       Long-Lasting Hippocampal Synaptic Protein	19	A plea for symptom-based research in psychiatry. Högre Utbildning, 2015, 6, 27660.	1.4	20
21       of literature and design of the Cerman Armed Forces PTSD biomarker study.       1.3       29         Psychoneuroendocrinology, 2015, 51, 4444458.       1.3       74         22       patients. Psychoneuroendocrinology, 2015, 55, 102-115.       1.3       74         23       and animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       1.5       28         24       miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       1.5       28         24       miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       1.5       28         24       antagonistic activity: evidence from a report of three cases. Therapeutic Advances in Psychopharmacology, 2015, 5, 208-213.       1.2       0         25       Arole for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.       1.3       26         26       The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders. Current Molecular Pharmacology, 2015, 9, 126-140.       0.7       33         27       Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease       0.6       85         28       Expression Levels in a Mouse Model of Posttra	20	Intranasally Applied Neuropeptide S Shifts a High-Anxiety Electrophysiological Endophenotype in the Ventral Hippocampus towards a "Normal"-Anxiety One. PLoS ONE, 2015, 10, e0120272.	1.1	20
22       patients. Psychoneuroendocrinology, 2015, 55, 102-115.       1.3       74         23       miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical and animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       1.5       28         24       and animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       1.2       0         24       antagonistic activity: evidence from a report of three cases. Therapeutic Advances in Psychopharmacology, 2015, 5, 208-213.       1.2       0         25       A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 5, 243-58.       1.3       26         26       The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders. Current Molecular 0.7       33         27       Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease 0.6       85         28       Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4, 66.       1.1       42         30       FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.       0.7       235         31       Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.	21	of literature and design of the German Armed Forces PTSD biomarker study.	1.3	29
23       and animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.       13       23         24       Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Therapeutic Advances in Psychopharmacology, 2015, 5, 208-213.       1.2       0         25       A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.       1.3       26         26       The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders. Current Molecular Pharmacology, 2015, 9, 126-140.       0.7       33         27       Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease Markers, 2013, 35, 43-54.       0.6       85         28       Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4, 66.       1.1       42         29       Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder. PLoS ONE, 2012, 7, e42603.       0.7       235         31       Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.       0.6       46         32       Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of       1.5       100	22		1.3	74
24antagonistic activity: evidence from a report of three cases. Therapeutic Advances in Psychopharmacology, 2015, 5, 208-213.1.2025A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.1.32626The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders. Current Molecular Pharmacology, 2015, 9, 126-140.0.73327Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease Markers, 2013, 35, 43-54.0.68528Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder.1.14729Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder. PLoS ONE, 2012, 7, e42603.1.14230FKS06 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.0.64631Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.0.646	23	miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical and animal studies. Journal of Psychiatric Research, 2015, 65, 1-8.	1.5	28
25and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.1.32626The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders. Current Molecular Pharmacology, 2015, 9, 126-140.0.73327Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease Markers, 2013, 35, 43-54.0.68528Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4, 66.1.34729Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder. PLoS ONE, 2012, 7, e42603.1.14230FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.0.723531Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.0.646	24	antagonistic activity: evidence from a report of three cases. Therapeutic Advances in	1.2	0
28       Pharmacology, 2015, 9, 126-140.       0.7       33         27       Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. Disease       0.6       85         27       Markers, 2013, 35, 43-54.       0.6       85         28       Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971       1.3       47         28       Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4, 66.       1.3       47         29       Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder.       1.1       42         30       FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.       0.7       235         31       Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.       0.6       46         29       Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of       1.1       42	25		1.3	26
27Markers, 2013, 35, 43-54.0.68528Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4, 66.1.34729Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder. PLoS ONE, 2012, 7, e42603.1.14230FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.0.723531Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.0.64639Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of1.5108	26		0.7	33
28Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4,1.34729Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder.1.14230FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.0.723531Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.0.64629Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of1.5108	27		0.6	85
29PLoŠ ONE, 2012, 7, e42603.1.14230FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.0.723531Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.0.64632Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of1.5102	28	Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. Frontiers in Psychiatry, 2013, 4,	1.3	47
30       Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.       0.7       233         31       Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.       0.6       46         32       Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of       15       102	29		1.1	42
Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. Journal of	30	FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. Biological Psychiatry, 2011, 70, 928-936.	0.7	235
	31	Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.	0.6	46
	32		1.5	103
33Epigenetic aspects of posttraumatic stress disorder. Disease Markers, 2011, 30, 77-87.0.621	33	Epigenetic aspects of posttraumatic stress disorder. Disease Markers, 2011, 30, 77-87.	0.6	21
FK506-binding Proteins 51 and 52 Differentially Regulate Dynein Interaction and Nuclear Translocation of the Glucocorticoid Receptor in Mammalian Cells. Journal of Biological Chemistry, 2005, 280, 1.6 545 4609-4616.	34	of the Glucocorticoid Receptor in Mammalian Cells. Journal of Biological Chemistry, 2005, 280,	1.6	545
<ul> <li>Essential Role of the Unusual DNA-binding Motif of BAC-1 for Inhibition of the Glucocorticoid</li> <li>Receptor. Journal of Biological Chemistry, 2003, 278, 4926-4931.</li> </ul>	35	Essential Role of the Unusual DNA-binding Motif of BAG-1 for Inhibition of the Glucocorticoid Receptor. Journal of Biological Chemistry, 2003, 278, 4926-4931.	1.6	46